BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 26631070)

  • 21. Targeting the Oncogenic Transcriptional Regulator MYB in Adenoid Cystic Carcinoma by Inhibition of IGF1R/AKT Signaling.
    Andersson MK; Afshari MK; Andrén Y; Wick MJ; Stenman G
    J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28954282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishment of PDX-derived salivary adenoid cystic carcinoma cell lines using organoid culture method.
    Takada K; Aizawa Y; Sano D; Okuda R; Sekine K; Ueno Y; Yamanaka S; Aoyama J; Sato K; Kuwahara T; Hatano T; Takahashi H; Arai Y; Nishimura G; Taniguchi H; Oridate N
    Int J Cancer; 2021 Jan; 148(1):193-202. PubMed ID: 32984947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Correlation of MYB/NFIB gene fusion with the grade and prognosis of head and neck adenoid cystic carcinoma and the concordance of two detection methods].
    Zhu YL; Li Y; Mu JL; Liu WC; Li X; Lu HZ
    Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):149-154. PubMed ID: 38281782
    [No Abstract]   [Full Text] [Related]  

  • 24. Adenoid cystic carcinoma of the lacrimal gland: MYB gene activation, genomic imbalances, and clinical characteristics.
    von Holstein SL; Fehr A; Persson M; Therkildsen MH; Prause JU; Heegaard S; Stenman G
    Ophthalmology; 2013 Oct; 120(10):2130-8. PubMed ID: 23725736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel chromosomal rearrangements and break points at the t(6;9) in salivary adenoid cystic carcinoma: association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcome.
    Mitani Y; Rao PH; Futreal PA; Roberts DB; Stephens PJ; Zhao YJ; Zhang L; Mitani M; Weber RS; Lippman SM; Caulin C; El-Naggar AK
    Clin Cancer Res; 2011 Nov; 17(22):7003-14. PubMed ID: 21976542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. UM-HACC-2A: MYB-NFIB fusion-positive human adenoid cystic carcinoma cell line.
    Warner KA; Oklejas AE; Pearson AT; Zhang Z; Wu W; Divi V; Rodriguez-Ramirez C; Castilho RM; Polverini PJ; Nör JE
    Oral Oncol; 2018 Dec; 87():21-28. PubMed ID: 30527239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A unifying gene signature for adenoid cystic cancer identifies parallel MYB-dependent and MYB-independent therapeutic targets.
    Gao R; Cao C; Zhang M; Lopez MC; Yan Y; Chen Z; Mitani Y; Zhang L; Zajac-Kaye M; Liu B; Wu L; Renne R; Baker HV; El-Naggar A; Kaye FJ
    Oncotarget; 2014 Dec; 5(24):12528-42. PubMed ID: 25587024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinically significant copy number alterations and complex rearrangements of MYB and NFIB in head and neck adenoid cystic carcinoma.
    Persson M; Andrén Y; Moskaluk CA; Frierson HF; Cooke SL; Futreal PA; Kling T; Nelander S; Nordkvist A; Persson F; Stenman G
    Genes Chromosomes Cancer; 2012 Aug; 51(8):805-17. PubMed ID: 22505352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adenoid Cystic Carcinoma With Striking Tubular Hypereosinophilia: A Unique Pattern Associated With Nonparotid Location and Both Canonical and Novel EWSR1::MYB and FUS::MYB Fusions.
    Weinreb I; Rooper LM; Dickson BC; Hahn E; Perez-Ordonez B; Smith SM; Lewis JS; Skalova A; Baněčková M; Wakely PE; Thompson LDR; Rupp NJ; Freiberger SN; Koduru P; Gagan J; Bishop JA
    Am J Surg Pathol; 2023 Apr; 47(4):497-503. PubMed ID: 36920022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation.
    West RB; Kong C; Clarke N; Gilks T; Lipsick JS; Cao H; Kwok S; Montgomery KD; Varma S; Le QT
    Am J Surg Pathol; 2011 Jan; 35(1):92-9. PubMed ID: 21164292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New developments in the molecular pathogenesis of head and neck tumors: a review of tumor-specific fusion oncogenes in mucoepidermoid carcinoma, adenoid cystic carcinoma, and NUT midline carcinoma.
    Bhaijee F; Pepper DJ; Pitman KT; Bell D
    Ann Diagn Pathol; 2011 Feb; 15(1):69-77. PubMed ID: 21238915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IGF2/IGF1R Signaling as a Therapeutic Target in MYB-Positive Adenoid Cystic Carcinomas and Other Fusion Gene-Driven Tumors.
    Andersson MK; Åman P; Stenman G
    Cells; 2019 Aug; 8(8):. PubMed ID: 31426421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted RNA sequencing in the routine clinical detection of fusion genes in salivary gland tumors.
    Bubola J; MacMillan CM; Demicco EG; Chami RA; Chung CT; Leong I; Marrano P; Onkal Z; Swanson D; Veremis BM; Weinreb I; Zhang L; Antonescu CR; Dickson BC
    Genes Chromosomes Cancer; 2021 Oct; 60(10):695-708. PubMed ID: 34176176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequent NFIB-associated Gene Rearrangement in Adenoid Cystic Carcinoma of the Vulva.
    Xing D; Bakhsh S; Melnyk N; Isacson C; Ho J; Huntsman DG; Gilks CB; Ronnett BM; Horlings HM
    Int J Gynecol Pathol; 2017 May; 36(3):289-293. PubMed ID: 27662035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathologic implications of Myb and Beta-catenin expression in adenoid cystic carcinoma.
    Park S; Vora M; van Zante A; Humtsoe J; Kim HS; Yom S; Agarwal S; Ha P
    J Otolaryngol Head Neck Surg; 2020 Jul; 49(1):48. PubMed ID: 32650834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of Myb protein and downstream target genes in salivary adenoid cystic carcinoma.
    Bell D; Roberts D; Karpowicz M; Hanna EY; Weber RS; El-Naggar AK
    Cancer Biol Ther; 2011 Oct; 12(7):569-73. PubMed ID: 21785271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of Outcome in Adenoid Cystic Carcinoma of Salivary Glands: A Clinicopathologic Study With Correlation Between MYB Fusion and Protein Expression.
    Xu B; Drill E; Ho A; Ho A; Dunn L; Prieto-Granada CN; Chan T; Ganly I; Ghossein R; Katabi N
    Am J Surg Pathol; 2017 Oct; 41(10):1422-1432. PubMed ID: 28719465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and characterization of xenograft model systems for adenoid cystic carcinoma.
    Moskaluk CA; Baras AS; Mancuso SA; Fan H; Davidson RJ; Dirks DC; Golden WL; Frierson HF
    Lab Invest; 2011 Oct; 91(10):1480-90. PubMed ID: 21709671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MYB promotes the growth and metastasis of salivary adenoid cystic carcinoma.
    Xu LH; Zhao F; Yang WW; Chen CW; Du ZH; Fu M; Ge XY; Li SL
    Int J Oncol; 2019 May; 54(5):1579-1590. PubMed ID: 30896785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma.
    Ho AL; Dunn L; Sherman EJ; Fury MG; Baxi SS; Chandramohan R; Dogan S; Morris LG; Cullen GD; Haque S; Sima CS; Ni A; Antonescu CR; Katabi N; Pfister DG
    Ann Oncol; 2016 Oct; 27(10):1902-8. PubMed ID: 27566443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.